FDA grants IND clearance for Asieris’ ulcerative colitis drug trial

FDA grants IND clearance for Asieris’ ulcerative colitis drug trial

Source: 
Clinical Trials Arena
snippet: 

The US Food and Drug Administration (FDA) has granted clearance for Asieris Pharmaceuticals’ Investigational New Drug (IND) application to begin a Phase Ib clinical trial of its oral drug, APL-1401, to treat moderately-to-severely active ulcerative colitis (UC).